| Bioactivity | Sontuzumab (AS1402) is a humanised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer[1]. |
| Target | Kd: ~1 nM (MUC1) |
| Invitro | Sontuzumab (huHMFG-1; 0-25 μg/mL) 对以下细胞诱导抗体依赖性细胞毒性 (ADCC): 乳腺癌细胞 ZR-75-1、乳腺癌患者的三种骨髓源性肿瘤细胞系 (KM22、1590、HG15) 和转染人 MUC1 基因的中国仓鼠卵巢 (CHO) 细胞。在 Sontuzumab 存在时，不表达人类 MUC1 的细胞系对 ADCC 不敏感[1][2]。 |
| Name | Sontuzumab |
| CAS | 372075-37-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pegram MD, et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73. [2]. Snijdewint FG, et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer. 2001 Jul 1;93(1):97-106. |